Related Experiment Video
Updated: Mar 2, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
[Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive
Qi Zheng1, Bangshan Liu1, Shuyin Xu2
1Mental Health Institute, Second Xiangya Hospital, Central South University; National Clinical Research Center for Mental Disorder; National Technology Institute of Psychiatry; Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha 410011, China.
Abstract:
Cognition deficit is one of the most common symptoms of schizophrenia, including abstract thinking and memory, and attention deficits. Previous studies have suggested that the improvement of cognition is very important for the recovery of disease and social function for the patients. Recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. This review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia. We hope that this review could guide clinical use of antipsychotics and provide new directions for future studies.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antipsychotic Drugs: Typical and Atypical Agents
